anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for detecting or monitoring tumor cells in an individual is provided which is based on routinely used imaging techniques such as magnetic resonance imaging (MRI) and ultrasound techniques. The detection and monitoring of the cells is carried out non-invasively by externally monitoring the level of oxygenation of the cells (measured as BOLD images) and blood flow to the cells (measured by Doppler ultrasound) in a tested tissue of the individual. The method may be used to identify regions in an individual that does not have a pre-known tumorigenic lesion as well as to detect regions having a high probability of comprising cells in a pre-suspected lesion of an individual (which may, for example be a region in where there is a high probability of existence of primary tumor cells based on analysis by routinely used methods). The method comprises use of an agent which administration to the individual or contact with the cells results in enhancement of the oxygen consumption of the cells detectable by the various imaging techniques. The activating agent may, for example, activate the cells by binding to a receptor specifically expressed by the cells. In addition, methods for evaluating the efficacy of anti-tumorigenic treatments based on measuring blood oxygenation levels and blood flow levels to the cells by imaging techniques are also provided. Furthermore, methods for enhancing the efficacy of anti-tumorigenic therapeutic treatments including chemotherapeutical drugs, antibodies, and irradiation treatments are provided which involve administration to the treated individual of an amount of an agent which enhances the oxygenation of the target cells and the blood flow to the target cells in the treated individual. The efficacy of chemical contrast agents used in conjunction with MRI or ultrasound is also enhanced by the provided method.
The invention belongs to the technical field of pharmaceutical chemistry, and particularly relates to a lysophosphatidic acid receptor antagonist and a preparation method thereof. The applicant has surprisingly found that the compounds of the present invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospects, and can be used for preventing or treating diseases or conditions related to LPAR 1. Applicants have also unexpectedly found that IC's of certain compounds of the present invention  50  Values can be as low as 300nM or less, even 50nM or less. Moreover, the compounds of the invention have better safety and CC  50  The range can be up to 200 mu M or more. Furthermore, the compounds of the present invention have good metabolic stability in humans, rats, mice, such excellent inhibitory activity being highly desirable for their application as LPAR1 inhibitors in the above diseases or conditions. In addition, the preparation method of the compound is simple, the reaction condition is mild, the product yield is high, and the compound is suitable for industrial production.
Without any intervention, investigators observed whether neonates received raw MOM during the first week of life. Accordingly, the neonates were grouped as "exposed" when they received any raw MOM before day 7, versus "unexposed" when they did not receive any raw MOM before day 7.
This study is a randomized, double blind, placebo-controlled clinical trial. It aims to demonstrate that (1) Chinese medicine prescription "Wu Zhu Yu Tang" can prevent Acute Mountain Sickness(AMS) (2) "Wu Zhu Yu Tang" can prevent AMS especially for Yang-Xu body constitution.

We will randomize 240 unacclimatized healthy adults. They will be randomized after stratification of the Yang-Xu score and the AMS history to receive Chinese medicine during one ascent and placebo during the other ascent. We will take them in Hehuan mountain for two days hike (24 hours) and an overnight over 3,000m. One month before the study, the subjects will fill the "Body Constitution Questionnaire BCQ" in order to evaluate their body constitution. Before, during and after the two days hike we will measure their blood pressure, heart rate and arterial oxygen saturation. The incidence of AMS will be measured by the Lake Louise Self Report (Lake Louise Score ≥4 with headache), we will also report the Lake Louise Clinical Assessment score and Lake Louise Functional Score.
Ketamine 50mg/1mL will be diluted with 9mL of normal saline to create 50mg in the 10mL syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
###  Telmisartan

As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar results may be anticipated in patients treated with telmisartan.

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen were observed. There has been no long-term use of telmisartan in patients with unilateral or bilateral renal artery stenosis but an effect similar to that seen with ACE inhibitors should be anticipated.

###  Hydrochlorothiazide

Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.
FIELD: chemical technology. SUBSTANCE: invention relates to the synthesis of macromolecular paramagnetic compounds used for magnetic resonance image making. Macromolecular paramagnetic compound of the general formula MM-(L-Ch-PM) m  where: MM - polysaccharide residue taken from the group consisting of dextran, hydroxyethylstarch and glycogen; L - binding group that is amino acid residue; Ch - residue of bifunctional chelating agent - aminopolycarboxylic acid; PM - paramagnetic metal ion chelated by Ch; m - positive number to obtain molecular mass of macromolecular paramagnetic compound up to 2 mln; bond MM-L is ester linkage and bond Ch-L - amide linkage. Invention relates to method of preparing above mentioned compound, diagnostic contrasting agent and method of preparing the diagnostic contrasting agent also. EFFECT: improved method of synthesis. 8 cl
Acquired factor V (FV) inhibitors are extremely rare and present with a broad spectrum ranging from asymptomatic laboratory anomalies to life-threatening critical bleeds. The overall rarity along with the heterogeneity of clinical presentations poses a challenge in diagnosis. There is currently no standard of care immunosuppressive therapy (IST) in these settings. Most patients in the literature receive multiple agents, including but not limited to combinations of IST and/or recombinant products.Here, we present a case of a man in his 50s who initially presented with oozing at peripheral IV and tracheostomy sites with intermittent epistaxis. He was later found to have an FV activity level of less than 1% and an FV inhibitor titre of 184 Bethesda units/mL. The patient was initially stabilised with fresh frozen plasma, platelets and tranexamic acid and treated with intravenous immunoglobulin and glucocorticoids. However, this resulted in only mild improvement in his coagulation studies. He was then treated with weekly doses of rituximab for 4 weeks with ongoing glucocorticoids without complications. This adds to the growing literature on rituximab as a possible treatment option for acquired FV inhibitors.
PURPOSE:To obtain the titled composition having excellent storage stability, especially hydrolysis resistance in the high-temperature storage of a tocopherol (derivative), by adding a nonionic surfactant to a composition containing tocopherol or its ester derivative and an anionic surfactant. CONSTITUTION:A nonionic surfactant is added in an amount of 0.1-5(wt)% to a composition composed of (A) 0.01-5%, especially 0.05-2% tocopherol or its ester derivative effective as a preventive or remedy for periodontosis by its pharmacological activity such as the blood flow promoting effect, etc. and (B) 0.1-5%, especially 0.3-3% anionic surfactant (especially a 8-18C alkylsulfuric acid ester) used as a frothing agent to improve the feeling to the oral cavity. The nonionic surfactant is preferably a fatty acid alkonolamide (e.g. lauric acid diethanolamide) having 8-18C fatty acid group and 2-3C alkanol group. The weight ratio of the nonionic surfactant to the anionic surfactant is preferably 1:5-5:1.
Muscular dystrophies (MDs) are genetically heterogeneous diseases characterized by primary skeletal muscle atrophy. The collapse of muscle structure and irreversible degeneration of tissues promote the occurrence of comorbidities, including cardiomyopathy and respiratory failure. Mitochondrial dysfunction leads to inflammation, fibrosis, and adipogenic cellular infiltrates that exacerbate the symptomatology of MD patients. Gastrointestinal disorders and metabolic anomalies are common in MD patients and may be determined by the interaction between the intestine and its microbiota. Therefore, the gut-muscle axis is one of the actors involved in the spread of inflammatory signals to all muscles. In this review, we aim to examine in depth how intestinal dysbiosis can modulate the metabolic state, the immune response, and mitochondrial biogenesis in the course and progression of the most investigated MDs such as Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy (MD1), to better identify gut microbiota metabolites working as therapeutic adjuvants to improve symptoms of MD.
Subjects who are included will recieve Hp eradication therapy based on antimicrobial susceptibility test. After the therapy, the subjects will be divided into two groups, the successful group and the failure group. The subjects who fail to eradicate the Hp after initial treatment and rescue treatment will go into the failure group. Otherwhile, they will go to the successful group.And then they wiil be followed up to observe the development of the gastric mucosa pathology. For mild atrophy gastritis, non- intestinal metaplasial gastritis, follow-up is performed every 2-3 years.For severe atrophy gastritis, intestinal metaplasial gastritis, follow-up is performed every 1-2 years. For patients wth high-grade intraepithelial neoplasia, they can be included 3 months after the endoscopic treatment, and the follow up will be performed at 6, 12 months after the treatment and then the follow up will be carried out every 1 year. For non-atrophic gastritis, no follow-up will be performed. All included patients will recieve a follow-up at the endpoint of 5 years. The follow-up includes endoscopy examination and serum test of PG I,PG II and gastrin 17.
The compound known as Sodium arsenite (NaAsO2), which is a prevalent type of inorganic arsenic found in the environment, has been strongly associated with liver fibrosis (LF), a key characteristic of nonalcoholic fatty liver disease (NAFLD), which has been demonstrated in our previous study. Our previous research has shown that exposure to NaAsO2 triggers the activation of hepatic stellate cells (HSCs), a crucial event in the development of LF. However, the molecular mechanism is still unknown. N6-methyladenosine (m6A) modification is the most crucial post-transcriptional modification in liver disease. Nevertheless, the precise function of m6A alteration in triggering HSCs and initiating LF caused by NaAsO2 remains unknown. Here, we found that NaAsO2 induced LF and HSCs activation through TGF-β/Smad signaling, which could be reversed by TGF-β1 knockdown. Furthermore, NaAsO2 treatment enhanced the m6A modification level both in vivo and in vitro. Significantly, NaAsO2 promoted the specific interaction of METTL14 and IGF2BP2 with TGF-β1 and enhanced the TGF-β1 mRNA stability. Notably, NaAsO2-induced TGF-β/Smad pathway and HSC-t6 cells activation might be avoided by limiting METTL14/IGF2BP2-mediated m6A modification. Our findings showed that the NaAsO2-induced activation of HSCs and LF is made possible by the METTL14/IGF2BP2-mediated m6A methylation of TGF-β1, which may open up new therapeutic options for LF brought on by environmental hazards.
Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of TDF [see Adverse Reactions (6.2)].

Prior to initiation of COMPLERA, and during treatment with COMPLERA, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus.

COMPLERA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple nonsteroidal anti-inflammatory drugs [NSAIDs]) [see Drug Interactions (7.4)]. Cases of acute renal failure after initiation of high-dose or multiple NSAIDs have been reported in HIV-infected patients with risk factors for renal dysfunction who appeared stable on TDF. Some patients required hospitalization and renal replacement therapy. Alternatives to NSAIDs should be considered, if needed, in patients at risk for renal dysfunction.

Persistent or worsening bone pain, pain in extremities, fractures, and/or muscular pain or weakness may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function in at-risk patients.

Emtricitabine and TDF are principally eliminated by the kidney; however, RPV is not. Since COMPLERA is a combination product and the dose of the individual components cannot be altered, COMPLERA is not recommended in patients with estimated creatinine clearance below 50 mL per minute [see Use in Specific Populations (8.6)].
Tumor necrosis has been reported to represent an independent prognostic factor in colorectal cancer, but its evaluation methods have not been described in sufficient detail to introduce tumor necrosis evaluation into clinical use. To study the potential of tumor necrosis as a prognostic indicator in colorectal cancer, criteria for 3 methods for its evaluation were defined: the average percentage method (tumor necrosis percentage of the whole tumor), the hotspot method (tumor necrosis percentage in a single hotspot), and the linear method (the diameter of the single largest necrotic focus). Cox regression models were used to calculate cancer-specific mortality hazard ratios (HRs) for tumor necrosis categories in 2 colorectal cancer cohorts with more than 1800 cases. For reproducibility assessment, 30 cases were evaluated by 9 investigators, and Spearman's rank correlation coefficients and Cohen's kappa coefficients were calculated. We found that all 3 methods predicted colorectal cancer-specific survival independent of other prognostic parameters, including disease stage, lymphovascular invasion, and tumor budding. The greatest multivariable HRs were observed for the average percentage method (cohort 1: HR for ≥ 40% vs. <3% 3.03, 95% CI, 1.93-4.78; cohort 2: HR for ≥ 40% vs. < 3% 2.97; 95% CI, 1.63-5.40). All 3 methods had high reproducibility, with the linear method showing the highest mean Spearman's correlation coefficient (0.91) and Cohen's kappa (0.70). In conclusion, detailed criteria for tumor necrosis evaluation were established. All 3 methods showed good reproducibility and predictive ability. The findings pave the way for the use of tumor necrosis as a prognostic factor in colorectal cancer.
In this study, each participant will receive a regimen of oral semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for a duration of twelve weeks. The dosage will begin at 3 mg/day for weeks 1-2, gradually increasing to 7 mg/day for weeks 3-4, 14 mg/day for weeks 5-6, 28 mg/day for weeks 7-8, and finally, to 42 mg/day for the last four weeks (weeks 9-12).
Each treatment cycle consists of 28 days. Patients will initially receive induction therapy with regorafenib (80 mg on days 1-21 of the 28-day cycle) and nivolumab (240 mg on days 1 and 15 of the 28-day cycle). Starting on cycle 2, day 1, patients will also receive FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h). If the patient is not a good candidate for induction regorafenib and nivolumab (i.e. symptomatic from a large burden of disease), 5-FU and oxaliplatin can be added during cycle 1 at the treating physician's discretion. 39 Patients will continue with this regimen until disease progression, unacceptable toxicity, or development of serious intercurrent illness. Treatment will be performed on the scheduled day (±7-day treatment window).
The present invention relates to a cosmetic composition containing extracts of more than one ingredient selected from among Llex rudingcha C. J. Tseng, Trapa japonica Flerov, Zizyphus jujuba Mill. var. inermis Bge leaves, Sorbus commixta Hedl, Eclipta prostrata L., and Rhodiola sachalinensis A. Bor as an active ingredient. The cosmetic composition inhibits the synthesis of triglycerides in adipocytes, thereby having an excellent slimming effect. Cosmetics using the cosmetic composition of the present invention is produced by the following steps: preparing a cosmetic composition for slimming, containing more than one extract selected from among medicinal herb extracts of Llex rudingcha C. J. Tseng, Trapa japonica Flerov, Zizyphus jujuba Mill. var. inermis Bge leaves, Sorbus commixta Hedl, Eclipta prostrata L., and Rhodiola sachalinensis A. Bor as an active ingredient; treating each extract sample to adipocyte precursor cells and measuring toxicity in the adipocyte precursor cells; testing an effect on inhibition of triglyceride synthesis; and adding 0.001-10 wt of the extracts of Llex rudingcha C. J. Tseng, Trapa japonica Flerov, Zizyphus jujuba Mill. var. inermis Bge leaves, Sorbus commixta Hedl, Eclipta prostrata L., and Rhodiola sachalinensis A. Bor per total weight of the cosmetic composition.
AIMS: This study aimed to investigate the association between the time to achieve walkability after cardiac surgery and the risk of cardiovascular disease after hospital discharge.
METHODS: We conducted a prospective cohort study involving 553 ambulatory patients aged 71.5 (range, 64.0-77.0) years who underwent cardiac surgery. All patients were divided into five groups based on the time to achieve walkability ≥100 m within 1, 2, 3, 4 or 5 days after cardiac surgery. We examined the risk of post-cardiovascular disease outcomes, including readmission due to heart failure, ischaemic heart disease and other cardiovascular disease, according to the time to achieve walkability with reference to 5 days using the Fine and Gray regression model, considering competing risks.
RESULTS: In the survival curve analysis, we examined the time to experience post-cardiovascular disease incidence after hospital discharge. During a median of 3.3 years of follow-up, 118 patients developed cardiovascular disease. We observed a positive association between the time to achieve walkability and cardiovascular disease risk, particularly heart failure. The multivariate hazard ratios (95% confidence intervals) for heart failure readmission were N/A (not assessed due to the sample size being too small) for 1 day, 0.31 (0.10-0.99) for 2 days, 0.60 (0.21-1.79) for 3 days and 0.76 (0.22-2.72) for 4 days (P for trend = 0.032).
CONCLUSIONS: The shorter walkability achievement time was associated with a lower risk of cardiovascular diseases, more specifically heart failure readmission, among patients who underwent cardiac surgery. The time required to achieve walkability is a useful predictor for cardiovascular diseases after hospital discharge.
BACKGROUND: The geriatric nutritional risk index (GNRI) is a prognostic indicator for several diseases, meanwhile, nutrition and inflammation play important roles in the disease progression of amyotrophic lateral sclerosis (ALS). However, the association between the GNRI and ALS remains unknown.
METHODS: 443 patients diagnosed with ALS were divided into two groups based on the GNRI levels. Associations between GNRI and survival time were analyzed using Kaplan-Meier curves and compared by the log-rank test. Univariate and multivariate analyses were used to assess their prognostic values for survival time. Spearman correlation analysis was used to evaluate the correlation coefficients between GNRI and other clinical variables.
RESULTS: No significant differences were found in diagnostic delay between the two groups. The onset age and disease progression rate (DPR) were significantly lower in high GNRI group while forced vital capacity (FVC), revised version of the ALS functional rating scale (ALSFRS-R), serum albumin and body mass index (BMI) were significantly lower in low GNRI group. Lower GNRI levels were linked with shorter ALS patients' survival time by Kaplan-Meier curves. The univariate and multivariate analysis identified the onset age, gender, onset site, diagnostic delay, DRP and GNRI as predictors of survival time in patients with ALS.
CONCLUSION: Nutritional status was closely corelated with ALS progression. The GNRI may be used as a potential prognostic indictor for ALS patients.
Provided herein are systems and methods of determining times of events. A server may receive a message from a client in response to an event. The message may identify a first time corresponding to a generation of the event and a second time corresponding to transmission of the message. The first time and the second time may be determined using a first clock of the client. The server may identify, using a second clock of the server, a third time at which the message is received at the server. The server may determine a fourth time based at least on the first time, the second time, and the third time. The fourth time may identify a time according to the second clock at which the event was generated at the client.
Oxidants participate in lymphocyte activation and function. We previously demonstrated that eliminating the activity of NADPH oxidase 2 (NOX2) significantly impaired the effectiveness of autoreactive CD8+ CTLs. However, the molecular mechanisms impacting CD8+ T cell function remain unknown. In the present study, we examined the role of NOX2 in both NOD mouse and human CD8+ T cell function. Genetic ablation or chemical inhibition of NOX2 in CD8+ T cells significantly suppressed activation-induced expression of the transcription factor T-bet, the master transcription factor of the Tc1 cell lineage, and T-bet target effector genes such as IFN-γ and granzyme B. Inhibition of NOX2 in both human and mouse CD8+ T cells prevented target cell lysis. We identified that superoxide generated by NOX2 must be converted into hydrogen peroxide to transduce the redox signal in CD8+ T cells. Furthermore, we show that NOX2-generated oxidants deactivate the tumor suppressor complex leading to activation of RheB and subsequently mTOR complex 1. These results indicate that NOX2 plays a nonredundant role in TCR-mediated CD8+ T cell effector function.